0001415889-24-010660.txt : 20240410
0001415889-24-010660.hdr.sgml : 20240410
20240410173955
ACCESSION NUMBER: 0001415889-24-010660
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240409
FILED AS OF DATE: 20240410
DATE AS OF CHANGE: 20240410
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tanimoto Sarina
CENTRAL INDEX KEY: 0001951291
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39756
FILM NUMBER: 24836735
MAIL ADDRESS:
STREET 1: C/O ARS PHARMACEUTICALS, INC.
STREET 2: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARS Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001671858
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811489190
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-771-9307
MAIL ADDRESS:
STREET 1: 11682 EL CAMINO REAL, SUITE 120
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Silverback Therapeutics, Inc.
DATE OF NAME CHANGE: 20160412
4
1
form4-04102024_090450.xml
X0508
4
2024-04-09
0001671858
ARS Pharmaceuticals, Inc.
SPRY
0001951291
Tanimoto Sarina
C/O ARS PHARMACEUTICALS, INC.
11682 EL CAMINO REAL, SUITE 120
SAN DIEGO
CA
92130
false
true
true
false
CHIEF MEDICAL OFFICER
1
Common Stock
3276854
D
Common Stock
2024-04-09
4
S
0
50000
9.2777
D
1646494
I
By Richard Lowenthal Charitable Remainder UniTrust Dated January 7, 2020
Common Stock
2024-04-09
4
S
0
50000
9.277
D
1898499
I
By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
Common Stock
1697447
I
By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
Common Stock
4126822
I
By Spouse
The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
The weighted average sales price for the transaction report was $9.2777,and the range of prices were between $9.13 and $9.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The weighted average sales price for the transaction report was $9.277,and the range of prices were between $9.13 and $9.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.
The Reporting Person is trustee of the trust.
/s/ Kathleen Scott, Attorney-in-Fact
2024-04-10